Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 4/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359480 | 0.88 | HDAC1 (0.39) | ACHE | |
| SCHEMBL14119632 | 0.87 | ACHE (0.31) | ACHE | |
| SCHEMBL12359620 | 0.86 | NOS3 (0.33) | ACHETAAR1 | |
| SCHEMBL12359488 | 0.86 | NOS3 (0.33) | ACHETAAR1 | |
| SCHEMBL12359621 | 0.85 | NOS3 (0.33) | ACHETAAR1 | |
| SCHEMBL12359557 | 0.85 | ACHE (0.41) | ACHE | |
| SCHEMBL16317649 | 0.83 | HDAC1 (0.34) | ACHE | |
| SCHEMBL12359622 | 0.83 | HDAC1 (0.34) | ACHE | |
| SCHEMBL12359494 | 0.83 | HDAC1 (0.34) | ACHE | |
| SCHEMBL12359567 | 0.82 | MTNR1A (0.37) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | ITGB3 800/4885ITGA2B 801/4885ASIC3 1135/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | ITGB3 800/4885ITGA2B 801/4885ASIC3 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.